

1. **Igea A***, Canovas B*, Sartori AA, Gomis RR, Paull TT, Isoda M, Perez-Montoyo H, Serra V, Gonzalez-Suarez E, Stracker T, Nebreda AR (*co-authors). Essential role of p38 α limiting chromosome instability in breast cancer. **Cancer Cell** (2018) Jun 11;33(6):1094-1110 (*co-authors)
2. del Barco Barrantes I, Otto Attolini CS, Slobodnyuk K, **Igea A**, Gregorio S, Gawrzak S, Gomis RR, Nebreda AR. Regulation of mammary limal cell fate and tumorigenesis by p38 α . **Stem Cell Reports** (2018) Jan 9;10(1):257-271.
3. Gómez-Miraya J, Palafox M, Pare L, Yoldi G, Ferrer I, Vila S, Galvan P, Pellegrini P, Perez-Montoyo H, **Igea A**, Muñoz P, Esteller M, Nebreda AR, Urriticoechea A, Morilla I, Pernas S, Climent F, Soler-Monso MT, Petit A, Serra V, Prat A, Gonzalez-Suarez E. Resistance to taxanes in triple-negative breast cancer associates with the dynamics of a CD49f+ tumor.initiating population. **Stem Cell Reports** (2017) May 9;8(5):1392-1407.
4. Jaeger S, **Igea A**, Arroyo R, Alcalde V, Canovas B, Orozco M, Nebreda AR, Aloy P. Pathway crosstalk quantification revelas novel synergistic drug combinations against breast cancer. **Cancer Research** (2017) Jan 15;77(2):459-469
5. Galanos P, Vougas K, Walter D, Polyzos A, Maya-Mendoza A, Haagensen EJ, Kokkalis A, Roumelioti FM, Gagos S, Tzetis M, Canovas B, **Igea A**, Ahuja AK, Zellweger R, Havaki S, Kanavakis E, Kletsas D, Roninson IB, Garbis SD, Lopes M, Nebreda A, Thanos D, Blow JJ, Townsend P, Sørensen CS, Bartek J, Gorgoulis VG. Chronic p53-independent p21 expression causes genòmic instability by deregulating replication licensing. **Nat Cell Biol** (2016) Jul;18(7):777-89
6. Mikolcevic P, Isoda M, Shibuya H, Del Barco Barrantes I, **Igea A**, Suja JA, Shackleton S, Watanabe Y, Nebreda AR. Essential role of the Cdk2 activator RingoA in meiotic telomere tethering to the nuclear envelope. **Nat Commun** (2016) Mar 30;7:11084
7. **Igea A**, Nebreda AR. The stress kinase p38a as a target for cancer tharaphy. **Cancer Research** (2015) 75(19):3997-4002
8. Giangarrà V, **Igea A**, Castellazzi CL, Bava FA, Mendez R. Global analysis of CPEBs reveals sequential and non-redundant functions in mitotic cell cycle. **PLoS One** (2015) 23;10(9)
9. **Igea A**, Gupta J, Nebreda AR. Targeting of non-oncogene addiction. **Aging** 7(8):525-6 (2015)
10. **Igea A***, Gupta J*, Papaioannou M, Lopez-Casas PP, Llonch E, Hidalgo M, Gorgoulis VG, Nebreda AR. Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors. **Oncotarget** (2015) 6(11):8539-51. (*co-authors)
11. Gupta J, del Barco Barrantes I, **Igea A**, Sakellariou S, Pateras IS, Gorgoulis VG, Nebreda AR. Dual function of p38a MAPK in colon cancer: suppression of colitis-associated tumor initiation but requirement for cancer cell survival. **Cancer Cell** (2014) 25(4):484-500
12. Pereira L, **Igea A**, Canovas B, Dolado I, Nebreda AR. Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK. **EMBO Mol Med** (2013) 5(11):1759-74
13. Amata I, Maffei M, **Igea A**, Gay M, Vilaseca M, Nebreda AR, Pons M. Multi-phosphorylation of the intrinsically disordered unique domain of c-Src studied by in-cell and real-time NMR spectroscopy. **Chembiochem** (2013) 14(14):1820-7
14. Pérez Y, Maffei M, **Igea A**, Amata I, Gairí M, Nebreda AR, Bernadó P, Pons M Lipid binding by the unique and SH- domains of c-Src suggests a new regulatory mechanism. **Sci Rep** (2013) 3:1295
15. Swat A, Dolado I, **Igea A**, Gomez-Lopez G, Pisano DG, Cuadrado A, Nebreda AR. Expression and funcional validation of new p38a transcriptional targets in tumorigenesis. **Biochem J** (2011) 434(3):549-58
16. **Igea A** and Mendez R. Meiosis requires a translational positive loop where CPEB1 ensures its replacement by CPEB4. **EMBO J** (2010) 29:2182-2193